# A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer

> **NCT07455071** · NA · NOT_YET_RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 9 (estimated)

## Conditions studied

- HRD-negative Epithelial Ovarian Cancer

## Interventions

- **BIOLOGICAL:** Tumor Neoantigen-Sensitized Autologous Dendritic Cell Injection (YS247)

## Key facts

- **NCT ID:** NCT07455071
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07455071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07455071, "A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07455071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*